Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2014
Pharmacy Choice - News - Pharmaceutical Development - October 20, 2014

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

10/20/14 - Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna
Today, Analysts Review released its research reports regarding AbbVie Inc., Gilead Sciences Inc., Pfizer Inc., Eli Lilly and Company and Aetna Inc.. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7291-100free. AbbVie Inc. Research Report s On October 16, 2014, Bloomberg reported that AbbVie I
10/20/14 - Advaxis Appoints David J. Mauro, M.D., Ph.D., as Chief Medical Officer
Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J. Mauro, M.D., Ph.D., as Executive Vice President, Chief Medical Officer of Advaxis. Dr. Mauro brings to Advaxis more than 14 years of experience in oncology drug development, clinical research, and medical affairs
10/20/14 - AgonOx's OX40 Platform Being Utilized in MedImmune's Phase 1 OX40 Agonist Study
MedImmune licensed the OX40 agonist platform in 2011 from AgonOx as the result of a partnership between the Providence Cancer Center and AgonOx, a spin-off company from the Providence Cancer Center. Providence Cancer Center, one of the sites selected by MedImmune to participate in the clinical trial, has recently enrolled their first patient.
10/20/14 - Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With...
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira in patients with moderate-to-severe plaque psoriasis met its primary endpoint. "Results from Amgen's biosimilar Phase 3 plaque psoriasis study met the primary endpoint
10/20/14 - Amgen's BiTE Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for the investigational bispecific T cell engager antibody construct, blinatumomab. As part of the acceptance, the FDA granted blinatumomab priority review with a Prescr
10/20/14 - Apricus Expands Development Pipeline With the In-Licensing of U.S. Rights for Fispemifene, a Phase 2b Ready Asset, From Forendo Pharma Targeting Urological Conditions in Men
Apricus Biosciences, Inc., today announced that it has licensed the U.S. development and commercialization rights for a novel selective estrogen receptor modulator, fispemifene, an investigational treatment for urological conditions in men, from Forendo Pharma, a private therapeutics company based in Finland. Apricus Chief Executive Office, Richa
10/20/14 - Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury
Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award with the California Institute of Regenerative Medicine, effective October 1, 2014. In August 2014, Asterias received clearance from the U.S. Food and Drug Administration to initiate the Phase 1/ 2 a clinical trial of AST-OPC1. "There are currently
10/20/14 - Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's ANA 2014 Annual Meeting Including Results from the...
Avanir Pharmaceuticals Announces Data Presentations at the American Neurological Association's ANA 2014 Annual Meeting Including Results from the Phase II Trial for Treatment of Agitation in Patients with Alzheimer's Disease. By a News Reporter-Staff News Editor at Clinical Trials Week Avanir Pharmaceuticals, Inc. announced that data from the pha
10/20/14 - Avanir Pharmaceuticals to Host Investor Briefing on October 15, 2014
By a News Reporter-Staff News Editor at Clinical Trials Week Avanir Pharmaceuticals, Inc. will host an Investor Relations Briefing on Wednesday, October 15, 2014 at 7:30 a.m. ET in New York City. At the meeting, members of the Avanir senior management team will provide a company update and discuss the results from the phase II clinical trial eval
10/20/14 - BioDelivery Sciences to Provide BUNAVAIL Launch Update
By a News Reporter-Staff News Editor at Pharma Business Week BioDelivery Sciences International, Inc. will host an investor update conference call and webcast to discuss the launch of BUNAVAIL? buccal film which has been approved by the U.S. Food and Drug Administration for the maintenance treatment of opioid dependence. Since FDA approval of B
10/20/14 - Boehringer Ingelheim's OFEV Approved by FDA as a Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis [Professional Services Close - Up]
Boehringer Ingelheim Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration approved OFEV capsules for oral use for the treatment of idiopathic pulmonary fibrosis. According to a release from the Company, granted Breakthrough Therapy designation during its review by the FDA, OFEV, capsules for oral use, taken twice daily, is the
10/20/14 - BrainStorm Reports Last Patient Visit in Phase 2a ALS Study
By a News Reporter-Staff News Editor at Pharma Business Week BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the last patient has completed the last visit in its phase 2 a clinical trial of NurOwn? in Amyotrophic Lateral Sclerosis, conducted at the Hadassah Medical
10/20/14 - Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small...
Bristol-Myers Squibb Announces Collaboration to Evaluate Opdivo nivolumab in Combination with Targeted Therapies from Novartis to Treat Non-Small Cell Lung Cancer NSCLC. By a News Reporter-Staff News Editor at Pharma Business Week Bristol-Myers Squibb Company announced the establishment of a clinical trial collaboration to evaluate the safety,...
10/20/14 - ChemoCentryx Releases Phase III SHIELD 4 Clinical Results In Patients With Crohn's Disease
ChemoCentryx, Inc.,, a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, today reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data were presented at the 79th American College of Gastroenterolog
10/20/14 - Clanotech receives orphan drug designation in the EU
Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency for prevention of scarring post glaucoma filtration surgery. The orphan drug designation will significantly shorten a future market approval process and reinforce market exclusivity for a...
10/20/14 - ClinTec International and Edinburgh Napier University's Masters Program Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the...
ClinTec International and Edinburgh Napier University's Masters Program Endorsed by Leading Multinational Top 20 Pharmaceutical Companies Through the Asia Training Consortium. By a News Reporter-Staff News Editor at Clinical Trials Week ClinTec International and Edinburgh Napier University are delighted to announce that the Asia Training...
10/20/14 - Combining High Standards of Care with an Efficient Research Environment: Richmond Pharmacology Extends Capacity for Early Phase Studies in Patients
Richmond Pharmacology has extended its capacity with an additional six-bed facility dedicated to screening and out-patient procedures for early phase studies in patients, complementing its existing 68- bed facility within Croydon University Hospital. Dr Keith Berelowitz, the Director of Operations commented: "It is the combination of medical...
10/20/14 - Cytokinetics Offers Update on Development Program for Tirasemtiv
Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead drug candidate from its skeletal muscle contractility program. As a result, Cytokinetics has initiated planning for a potential Phase III clinical trial of tirasemtiv that could begin in 2015.. BENEFIT-ALS is the first clinical trial in patients wi
10/20/14 - Cytokinetics Provides Development Program Update for Tirasemtiv
Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For Tirasemtiv SOUTH SAN FRANCISCO, CA, October 20, 2014- Cytokinetics, Incorporated provided a program update today relating to tirasemtiv, the company's lead d
10/20/14 - CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data in Soft Tissue Sarcoma in Cancer, the Peer-Reviewed Journal of the American Cancer Society
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that a paper, titled "A Phase 1 b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society. The paper discusses results
10/20/14 - Data on Clinical Trials and Studies Detailed by Researchers at Turku University Hospital (Voice Quality After Treatment of Early Vocal Cord Cancer: A...
Data on Clinical Trials and Studies Detailed by Researchers at Turku University Hospital. According to news reporting originating in Turku, Finland, by NewsRx journalists, research stated, "Early laryngeal cancer is usually treated with either transoral laser surgery or radiation therapy. The news reporters obtained a quote from the research from T
10/20/14 - DGAP-News: MOLOGEN AG: Successful investigator meetings for IMPALA colorectal cancer trial
DGAP-News: MOLOGEN AG/ Key word: Study MOLOGEN AG: Successful investigator meetings for IMPALA colorectal cancer trial 20.10. 2014/ 08:00- Berlin, October 20, 2014- MOLOGEN AG, a biotechnology company focused on cancer immunotherapy, has organized the first set of investigator meet
10/20/14 - Eisai Announces FDA Acceptance of Supplemental New Drug Application for Antiepileptic Drug Perampanel as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
Eisai Inc. announced today that the U.S. Food and Drug Administration accepted for review the company's Supplemental New Drug Application for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic seizures, a severe form of seizures, in patients 12 years and older. FYCOMPA? CIII, which
10/20/14 - European Commission Approves IMBRUVICATM in Two Forms of Blood Cancer; First-in-class BTK inhibitor for complex orphan diseases CLL and MCL
In the European Economic Area, Janssen is the marketing authorisation holder. Janssen affiliates market IMBRUVICA in EMEA as well as the rest of the world, except for the United States, where both companies co-market it. The decision from the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use of t
10/20/14 - FDA Grants Fast Track Designation to NurOwn? for the Treatment of ALS
By a News Reporter-Staff News Editor at Clinical Trials Week BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the United States Food and Drug Administration has designated NurOwn? as a Fast Track product for the treatment of amyotrophic lateral sclerosis.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415